AbbVie and Genmab's Epkinly succeeds in late-stage first-line DLBCL trial, challenging Roche's Polivy

AbbVie and Genmab announced that their T‑cell engager Epkinly met its primary endpoints in a late‑stage study evaluating first‑line treatment for diffuse large B‑cell lymphoma (DLBCL). The trial demonstrated the therapy’s efficacy and safety in the intended patient population.

The positive result positions Epkinly as a potential alternative to Roche’s antibody‑drug conjugate Polivy, which currently holds a prominent role in the DLBCL market. Analysts see the data as a possible shift in treatment paradigms for newly diagnosed patients.

Both companies said the data clears the path toward regulatory submissions and commercial launch plans, aiming to bring the therapy to patients as soon as possible. Further updates are expected as they engage health authorities worldwide.